Opus Genetics
Opus Genetics' revenue rose 29.1% to $14 million in fiscal 2025. Its operating margin was −271.9%, up from −564.7% a year earlier. The diluted share count rose 132.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Opus Genetics does
Opus Genetics is a clinical-stage drug company developing gene therapies to restore vision and prevent blindness in people with inherited retinal diseases, which are genetic conditions that damage the light-sensing tissue at the back of the eye. Its gene therapies are meant to be one-time treatments that address the genetic cause.
Its pipeline has seven gene therapy programs that use adeno-associated virus (AAV) vectors to deliver genes into cells. The lead programs are OPGx-LCA5 and OPGx-BEST1, and others target the genes RHO, CNGB1, RDH12, NMNAT1 and MERTK. It also has Phentolamine Ophthalmic Solution 0.75%, an eye drop approved by the FDA to reverse pharmacologically induced dilation of the pupil, which it is studying for other uses such as presbyopia, the loss of near vision with age.
The company licensed that eye drop to Viatris, which launched it in April 2024 under the brand name RYZUMVI. Opus was founded in 2018 as Ocuphire Pharma, and it took its current form after acquiring a gene therapy company in October 2024. It says it has no sales or marketing system of its own.
Its biggest risks, as it describes them
- It has not earned significant revenue from product sales and expects losses for the foreseeable future.
- It will need substantial additional capital, and raising it may dilute shareholders.
- Its gene therapies use new technology that is hard to develop and make, and trials may fail or be delayed.
- It depends heavily on its pipeline and on finding strategic partners, and has no sales infrastructure of its own.
Income statement
Opus Genetics lost money in fiscal 2025: a net loss of $50 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 25 | 43 | 50 | 30 | 45 |
| Debt incl. finance leases | — | — | — | 0 | 1 |
| Net debt (negative means net cash) | — | — | — | −30 | −44 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | 0.0x | 0.1x |
| Interest coverage | −11,352.5x | 2,025.1x | — | — | −299.2x |
| Current ratio | 6.8x | 17.8x | 13.3x | 3.2x | 6.4x |
| Quick ratio | 6.8x | 17.8x | 13.3x | 3.2x | 6.4x |
Cash flow
Projections
Project Opus Genetics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $323,890 of Opus Genetics shares on the open market, and 7 insiders sold $16.6 million, $127,120 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Robert E. GagnonChief Financial Officer | Sold plan | 28,000 | $4.54 | $127,120 | Form 4 |
| Jul 23, 2026 | George MagrathChief Executive Officer, Director | Sold | 9,475 | $2.95 | $27,951 | Form 4 |
| Jul 23, 2026 | Robert E. GagnonChief Financial Officer | Sold | 7,783 | $2.95 | $22,960 | Form 4 |
| Jul 23, 2026 | Benjamin R YerxaPresident, Director | Sold | 7,429 | $2.97 | $22,064 | Form 4 |
| Jul 23, 2026 | Joseph K SchachleChief Operating Officer | Sold | 4,644 | $2.94 | $13,653 | Form 4 |
| May 18, 2026 | Foundation Fighting Blindness Retinal Degeneration FundDirector | Sold | 1,700,000 | $4.35 | $7.4 million | Form 4 |
| Apr 23, 2026 | George MagrathChief Executive Officer, Director | Sold | 9,511 | $5.22 | $49,647 | Form 4 |
| Apr 23, 2026 | Robert E. GagnonChief Financial Officer | Sold | 7,842 | $5.18 | $40,622 | Form 4 |
| Apr 23, 2026 | Ashwath JayagopalChief Scientific & Dev. Ofc. | Sold | 7,542 | $5.19 | $39,143 | Form 4 |
| Apr 23, 2026 | Benjamin R YerxaPresident, Director | Sold | 7,470 | $5.24 | $39,143 | Form 4 |
| Apr 23, 2026 | Joseph K SchachleChief Operating Officer | Sold | 4,697 | $5.22 | $24,518 | Form 4 |
| Apr 23, 2026 | Rabourn Amy ZarembaHead of Fin. Quality Assurance | Sold | 1,641 | $5.20 | $8,533 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 3 of 8 |
| Rule of 40 | — | — | — |
| Altman Z'' | 12.79 | −18.48 | −11.42 |
| Accruals ratio | −17.2% | −70.4% | −32.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | — | — | 3 of 8 |
Compare
Put Opus Genetics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Opus Genetics | FY25 | 29.1% | −271.9% | — | — | — | 3 | |
| Pyxis Oncology | FY25 | −14.2% | −609.2% | −458.3% | — | — | — | Compare |
| Tonix Pharmaceuticals | FY25 | 29.9% | −959.0% | −787.5% | — | — | — | Compare |
| Evommune | FY25 | 85.7% | −623.6% | −589.8% | — | — | — | Compare |
| ProQR Therapeutics | FY25 | −15.9% | −273.1% | −338.3% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | 3 | 0 | 1 | 40 | 19 | 11 | 14 |
| Revenue growth | — | — | — | — | −100.0% | — | 6,665.7% | −52.2% | −42.3% | 29.1% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 10 | 11 | 13 | 6 | 7 | 15 | 14 | 18 | 27 | 31 |
| Operating income | −16 | −17 | −20 | −4 | −20 | −23 | 18 | −11 | −62 | −39 |
| Net income | −9 | −25 | −14 | −6 | −25 | −57 | 18 | −10 | −58 | −50 |
| Diluted EPS (US$) | −0.43 | −0.92 | −5.25 | −2.17 | −5.28 | −3.82 | 0.87 | −0.46 | −2.15 | −0.80 |
| Diluted shares (millions) | 22 | 27 | 3 | 3 | 5 | 15 | 21 | 22 | 27 | 62 |
| Cash flow | ||||||||||
| Cash from operations | −13 | −15 | −19 | −4 | −7 | −19 | 14 | −1 | −26 | −35 |
| Capital expenditure | — | — | — | 0 | 0 | — | — | — | — | — |
| Free cash flow | — | — | — | −4 | −7 | — | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 4 | 3 | 3 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 12 | 9 | 9 | 12 | 16 | 25 | 43 | 50 | 30 | 45 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | 0 | 1 |
| Total assets | 21 | 28 | 16 | 2 | 18 | 26 | 49 | 54 | 37 | 50 |
| Total liabilities | 4 | 12 | 6 | 9 | 31 | 4 | 3 | 4 | 11 | 35 |
| Shareholders' equity | 17 | 17 | −2 | −8 | −14 | 22 | 46 | 50 | 7 | 15 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | −139.8% | — | −3,854.8% | 45.7% | −55.5% | −564.7% | −271.9% |
| Net margin | — | — | — | −205.6% | — | −9,625.3% | 44.9% | −52.4% | −523.4% | −349.3% |
| Free cash flow margin | — | — | — | −120.6% | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −52.0% | −149.6% | −190.7% | — | — | −1,295.1% | 52.3% | −20.8% | −203.2% | −449.4% |
| Return on assets | −40.6% | −102.5% | −64.8% | −69.2% | −252.9% | −259.1% | 47.7% | −19.4% | −126.7% | −113.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |